Across TCGA pan-cancer cohorts, PRR22 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRR22 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PRR22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR22 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, PRAD, and UCEC are the cancer types where PRR22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.161	0.783	.006	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.635	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRR22 tumor-vs-normal RNA expression · all PRR22 data types